InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Liabilities and Shareholders Equity of $9.1 million for Q1 2026, down 1.57% year-over-year from $9.3 million in Q1 2025, and down 18.39% quarter-over-quarter from $11.2 million in Q4 2025.
InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 1.57% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $49.3 million (up 22.95% YoY), while the FY2025 annual figure was $15.6 million, up 31.78% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $9.1 million, down from $11.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $16.9 million in Q4 2022, with the low at $8.5 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $13.4 million (2024), against an average of $12.8 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 44.27% in 2024, then surged 31.78% in 2025.
- InMed Pharmaceuticals' Liabilities and Shareholders Equity stood at $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then sank by 44.27% to $8.5 million in 2024, then jumped by 31.63% to $11.2 million in 2025, then retreated by 18.39% to $9.1 million in 2026.
- Business Quant data shows INM's Liabilities and Shareholders Equity at $9.1 million in Q1 2026, $11.2 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | 9.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.13 Mn |
| Dec 31, 2025 | 11.19 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 15.58 Mn |
| Mar 31, 2025 | 9.28 Mn |
| Dec 31, 2024 | 8.50 Mn |
| Sep 30, 2024 | 10.47 Mn |
| Jun 30, 2024 | 11.82 Mn |
| Mar 31, 2024 | 13.36 Mn |
| Dec 31, 2023 | 15.26 Mn |
| Sep 30, 2023 | 10.92 Mn |
| Jun 30, 2023 | 14.11 Mn |
| Mar 31, 2023 | 14.73 Mn |
| Dec 31, 2022 | 16.92 Mn |
| Sep 30, 2022 | 14.58 Mn |
| Jun 30, 2022 | 12.79 Mn |
| Mar 31, 2022 | 15.49 Mn |
| Dec 31, 2021 | 19.38 Mn |
| Sep 30, 2021 | 17.33 Mn |
| Jun 30, 2021 | 9.78 Mn |